A Randomized, Prospective Trial Comparing the Efficacy of Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections Using Insulin Glargine
Article Figures & Tables
Figures
- Figure 1—
HbA1c levels in the two treatment groups. The difference between CSII (⧫) and glargine (▪) at baseline is not significant. At 16 weeks, HbA1c levels in the CSII group were significantly lower than base-line (P < 0.02) and versus glargine (P < 0.05).
- Figure 2—
Mean fingerstick blood glucose levels for each meal. The difference between CSII (□) and glargine (▪) at breakfast is nonsignificant. The differences between CSII and glargine at all other time points are significant (P < 0.001)
Tables
- Table 1—
Baseline clinical characteristics of the two treatment groups
CSII MDI P n 16 16 — Age (years) 12.5 ± 3.2 13 ± 2.8 0.637 Sex (F/M) 10/6 8/8 0.722 Race (white/Hispanic/black) 11/3/2 13/2/1 0.705 Duration of diabetes (years) 6.8 ± 3.8 5.6 ± 4.0 0.391 Initial treatment (no. of injections) 12 b.i.d./4 MDI 14 b.i.d./2 MDI 0.654 TDD prestudy enrollment (units/kg) 1.4 ± 0.5 1.1 ± 0.3 0.087 Data are means ± SD.
- Table 2—
Basal/bolus doses at 16 weeks in the two treatment groups
CSII MDI P n 16 16 — TDD (units/kg) 0.9 ± 0.2 1.2 ± 0.2 0.003 Daily basal dose (units/kg) 0.6 ± 0.1 0.7 ± 0.1 0.137 Carbohydrate-to-insulin ratio (no. of grams per 1 unit insulin) 14 ± 7 10 ± 3 0.071 No. daily basal rates 5.4 ± 1.0 — — Mean day (7:00 a.m. to 9:00 p.m.) rate 1.6 ± 0.8 — — Mean night (10:00 p.m. to 6:00 a.m.) rate 1.4 ± 0.7 — — Data are means ± SD.
In this Issue
July 2004, 27(7)
A Randomized, Prospective Trial Comparing the Efficacy of Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections Using Insulin Glargine
